Weight Loss
16 peptides
5-Amino-1MQ
Published sources checked
A source-linked reference on the identity and evidence context of 5-Amino-1MQ. Sources checked 6 September 2026.
Qualified clinical review pending
AOD-9604
Published sources checked
A source-linked reference on the identity and evidence context of AOD-9604. Sources checked 6 September 2026.
Qualified clinical review pending
Adipotide
Published sources checked
A source-linked reference on the identity and evidence context of Adipotide. Sources checked 6 September 2026.
Qualified clinical review pending
CagriSema (Cagrilintide + Semaglutide)
Published sources checked
The studied cagrilintide and semaglutide combination, with trial population, outcomes and formulation limits.
Qualified clinical review pending
Cagrilintide
Published sources checked
What human trials of this amylin analogue show, their limits, and the current U.S. regulatory context.
Qualified clinical review pending
Dulaglutide
Published sources checked
A source-linked medicine reference on Dulaglutide, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
HGH Fragment 176-191
Published sources checked
A source-linked reference on the identity and evidence context of HGH Fragment 176-191. Sources checked 6 September 2026.
Qualified clinical review pending
Liraglutide
Published sources checked
A source-linked medicine reference on Liraglutide, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Mazdutide
Published sources checked
Human weight-management research on a GLP-1 and glucagon agonist, with country-specific approval context.
Qualified clinical review pending
Pramlintide
Published sources checked
A source-linked medicine reference on Pramlintide, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Retatrutide
Published sources checked
Selected human research on a triple-receptor agonist, including trial limits, adverse events and U.S. status.
Qualified clinical review pending
Retatrutide + Cagrilintide Blend
Identity unresolved
A component-by-component evidence check that separates this proposed mixture from CagriSema.
Qualified clinical review pending
Semaglutide
Published sources checked
A source-linked medicine reference on Semaglutide, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Survodutide
Published sources checked
The identity and selected clinical evidence for survodutide, with completion and tolerability limits.
Qualified clinical review pending
Tesofensine
Published sources checked
A source-linked reference on the identity and evidence context of Tesofensine. Sources checked 6 September 2026.
Qualified clinical review pending
Tirzepatide
Published sources checked
A source-linked medicine reference on Tirzepatide, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
GH Optimisation
12 peptides
CJC-1295
Published sources checked
A source-linked reference on the identity and evidence context of CJC-1295. Sources checked 6 September 2026.
Qualified clinical review pending
CJC-1295 (with DAC)
Published sources checked
A source-linked reference on the identity and evidence context of CJC-1295 (with DAC). Sources checked 6 September 2026.
Qualified clinical review pending
CJC-1295/Ipamorelin Blend
Identity unresolved
Evidence for the named components and why it does not validate a mixed growth-hormone product.
Qualified clinical review pending
GHRP-2
Published sources checked
A source-linked reference on the identity and evidence context of GHRP-2. Sources checked 6 September 2026.
Qualified clinical review pending
GHRP-6
Published sources checked
A source-linked reference on the identity and evidence context of GHRP-6. Sources checked 6 September 2026.
Qualified clinical review pending
HGH (Human Growth Hormone)
Published sources checked
A source-linked medicine reference on HGH (Human Growth Hormone), its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Hexarelin
Published sources checked
A source-linked reference on the identity and evidence context of Hexarelin. Sources checked 6 September 2026.
Qualified clinical review pending
Ipamorelin
Published sources checked
A source-linked reference on the identity and evidence context of Ipamorelin. Sources checked 6 September 2026.
Qualified clinical review pending
MK-677 (Ibutamoren)
Published sources checked
A source-linked reference on the identity and evidence context of MK-677 (Ibutamoren). Sources checked 6 September 2026.
Qualified clinical review pending
Sermorelin
Published sources checked
A source-linked reference on the identity and evidence context of Sermorelin. Sources checked 6 September 2026.
Qualified clinical review pending
Tesamorelin
Published sources checked
A source-linked medicine reference on Tesamorelin, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Tesamorelin + Ipamorelin Blend
Identity unresolved
How this blend differs from prescription tesamorelin and what the cited component sources actually cover.
Qualified clinical review pending
Healing & Recovery
7 peptides
ARA-290
Published sources checked
A source-linked reference on the identity and evidence context of ARA-290. Sources checked 6 September 2026.
Qualified clinical review pending
BPC-157
Published sources checked
A factual reference on BPC-157 regulatory context and evidence limits. Sources checked 6 September 2026; qualified clinical review pending.
Qualified clinical review pending
BPC-157 + TB-500 Blend
Identity unresolved
Why a commercial blend cannot be treated as equivalent to the small BPC-157 and thymosin beta-4 study.
Qualified clinical review pending
Cartalax
Published sources checked
A source-linked reference on the Cartalax research label and its evidence limits. Sources checked 6 September 2026.
Qualified clinical review pending
TB-500
Published sources checked
A source-linked reference on the identity and evidence context of TB-500. Sources checked 6 September 2026.
Qualified clinical review pending
TB-500 Fragment
Published sources checked
A source-linked reference on the identity and evidence context of TB-500 Fragment. Sources checked 6 September 2026.
Qualified clinical review pending
Teriparatide
Published sources checked
A source-linked medicine reference on Teriparatide, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Longevity
18 peptides
AICAR
Published sources checked
A source-linked reference on the identity and evidence context of AICAR. Sources checked 6 September 2026.
Qualified clinical review pending
Cardiogen
Published sources checked
A source-linked reference on Cardiogen in a rat organotypic-culture study. Sources checked 6 September 2026.
Qualified clinical review pending
EPO (Erythropoietin)
Published sources checked
A source-linked medicine reference on EPO (Erythropoietin), its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Epithalon
Published sources checked
A source-linked reference on the identity and evidence context of Epithalon. Sources checked 6 September 2026.
Qualified clinical review pending
FOXO4-DRI
Published sources checked
A source-linked reference on the identity and evidence context of FOXO4-DRI. Sources checked 6 September 2026.
Qualified clinical review pending
GHK-Cu
Published sources checked
A source-linked reference on the identity and evidence context of GHK-Cu. Sources checked 6 September 2026.
Qualified clinical review pending
Glutathione (Injectable)
Published sources checked
A source-linked reference on the identity and evidence context of Glutathione (Injectable). Sources checked 6 September 2026.
Qualified clinical review pending
Humanin
Published sources checked
A source-linked reference on the identity and evidence context of Humanin. Sources checked 6 September 2026.
Qualified clinical review pending
Livagen
Published sources checked
A source-linked reference on Livagen in cultured lymphocytes from older people. Sources checked 6 September 2026.
Qualified clinical review pending
MOTS-c
Published sources checked
A source-linked reference on the identity and evidence context of MOTS-c. Sources checked 6 September 2026.
Qualified clinical review pending
N-Acetyl Epithalon Amidate
Identity unresolved
A reference record for N-Acetyl Epithalon Amidate. Its exact identity is unresolved after targeted source searches on 6 September 2026.
Qualified clinical review pending
NAD+ (Injectable)
Published sources checked
A source-linked reference on the identity and evidence context of NAD+ (Injectable). Sources checked 6 September 2026.
Qualified clinical review pending
Ovagen
Published sources checked
A source-linked reference on Ovagen’s EDL identity as presented in a 2022 ultrashort-peptide review. Sources checked 6 September 2026.
Qualified clinical review pending
PNC-27
Published sources checked
A source-linked reference on the identity and evidence context of PNC-27. Sources checked 6 September 2026.
Qualified clinical review pending
Pancragen
Published sources checked
A source-linked reference on Pancragen in experimental pancreatic models. Sources checked 6 September 2026.
Qualified clinical review pending
SLU-PP-332
Published sources checked
A source-linked reference on the identity and evidence context of SLU-PP-332. Sources checked 6 September 2026.
Qualified clinical review pending
SS-31 (Elamipretide)
Published sources checked
Elamipretide’s specific U.S. Barth syndrome approval, the evidence supporting it, and limits on broader claims.
Qualified clinical review pending
Vesugen
Published sources checked
A source-linked reference on Vesugen and the KED tripeptide in experimental research. Sources checked 6 September 2026.
Qualified clinical review pending
Cognitive
13 peptides
Adamax (Adamantane Semax)
Identity unresolved
A reference record for Adamax (Adamantane Semax). Its exact identity is unresolved after targeted source searches on 6 September 2026.
Qualified clinical review pending
Cerebrolysin
Published sources checked
A source-linked reference on the identity and evidence context of Cerebrolysin. Sources checked 6 September 2026.
Qualified clinical review pending
Cortagen
Published sources checked
A source-linked reference on the identity and evidence context of Cortagen. Sources checked 6 September 2026.
Qualified clinical review pending
Dihexa
Published sources checked
A source-linked reference on the identity and evidence context of Dihexa. Sources checked 6 September 2026.
Qualified clinical review pending
NA-Selank Amidate
Identity unresolved
A reference record for NA-Selank Amidate. Its exact identity is unresolved after targeted source searches on 6 September 2026.
Qualified clinical review pending
NA-Semax Amidate
Published sources checked
A source-linked reference on the named modified Semax compound and its evidence boundary. Sources checked 6 September 2026.
Qualified clinical review pending
Oxytocin
Published sources checked
A source-linked medicine reference on Oxytocin, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
P21 (Adamantane)
Identity unresolved
A reference record for P21 (Adamantane). Its exact identity is unresolved after targeted source searches on 6 September 2026.
Qualified clinical review pending
P21 (Cerebrolysin alternative)
Identity unresolved
A reference record for P21 (Cerebrolysin alternative). Its exact identity is unresolved after targeted source searches on 6 September 2026.
Qualified clinical review pending
P21
Identity unresolved
A reference record for P21. A source confirming the intended peptide is needed to connect this catalogue entry to the research literature.
Qualified clinical review pending
PE-22-28
Published sources checked
A source-linked reference on PE 22-28 in cell and mouse experiments. Sources checked 6 September 2026.
Qualified clinical review pending
Selank
Published sources checked
A source-linked reference on the identity and evidence context of Selank. Sources checked 6 September 2026.
Qualified clinical review pending
Semax
Published sources checked
A source-linked reference on the identity and evidence context of Semax. Sources checked 6 September 2026.
Qualified clinical review pending
Immune Support
9 peptides
Bronchogen
Published sources checked
A source-linked reference on the identity and evidence context of Bronchogen. Sources checked 6 September 2026.
Qualified clinical review pending
Chonluten
Published sources checked
A source-linked reference on Chonluten’s EDG identity and a limited THP-1 cell-culture experiment. Sources checked 6 September 2026.
Qualified clinical review pending
Crystagen
Published sources checked
A source-linked reference on Crystagen in an ageing-spleen experiment. Sources checked 6 September 2026.
Qualified clinical review pending
KPV
Published sources checked
A source-linked reference on the identity and evidence context of KPV. Sources checked 6 September 2026.
Qualified clinical review pending
LL-37
Published sources checked
A source-linked reference on the identity and evidence context of LL-37. Sources checked 6 September 2026.
Qualified clinical review pending
Thymalin
Published sources checked
A source-linked reference on Thymalin as a thymus-derived polypeptide complex. Sources checked 6 September 2026.
Qualified clinical review pending
Thymosin Alpha-1
Published sources checked
A source-linked reference on the identity and evidence context of Thymosin Alpha-1. Sources checked 6 September 2026.
Qualified clinical review pending
VIP (Vasoactive Intestinal Peptide)
Published sources checked
A source-linked reference on the identity and evidence context of VIP (Vasoactive Intestinal Peptide). Sources checked 6 September 2026.
Qualified clinical review pending
Vilon
Published sources checked
A source-linked reference on Vilon in thymic-peptide literature. Sources checked 6 September 2026.
Qualified clinical review pending
Sexual Health
7 peptides
Gonadorelin
Published sources checked
A source-linked medicine reference on Gonadorelin, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
HCG (Human Chorionic Gonadotropin)
Published sources checked
A source-linked medicine reference on HCG (Human Chorionic Gonadotropin), its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
HMG (Human Menopausal Gonadotropin)
Published sources checked
A source-linked medicine reference on HMG (Human Menopausal Gonadotropin), its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Kisspeptin-10
Published sources checked
A source-linked reference on the identity and evidence context of Kisspeptin-10. Sources checked 6 September 2026.
Qualified clinical review pending
PT-141
Published sources checked
A source-linked medicine reference on PT-141, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Prostamax
Published sources checked
A source-linked reference on Prostamax in a rat organotypic-culture study. Sources checked 6 September 2026.
Qualified clinical review pending
Testagen
Published sources checked
A source-linked reference on Testagen as a named short peptide in experimental literature. Sources checked 6 September 2026.
Qualified clinical review pending
Sleep & Recovery
3 peptides
DSIP (Delta Sleep-Inducing Peptide)
Published sources checked
A source-linked reference on the identity and evidence context of DSIP (Delta Sleep-Inducing Peptide). Sources checked 6 September 2026.
Qualified clinical review pending
Melatonin (Injectable)
Published sources checked
A source-linked reference on the identity and evidence context of Melatonin (Injectable). Sources checked 6 September 2026.
Qualified clinical review pending
Pinealon
Published sources checked
A source-linked reference on Pinealon in oxidative-stress cell experiments. Sources checked 6 September 2026.
Qualified clinical review pending
Muscle Growth
4 peptides
ACE-031
Published sources checked
A source-linked reference on the identity and evidence context of ACE-031. Sources checked 6 September 2026.
Qualified clinical review pending
IGF-1 LR3
Published sources checked
A source-linked reference on the identity and evidence context of IGF-1 LR3. Sources checked 6 September 2026.
Qualified clinical review pending
MGF (Mechano Growth Factor)
Published sources checked
A source-linked reference on the identity and evidence context of MGF (Mechano Growth Factor). Sources checked 6 September 2026.
Qualified clinical review pending
PEG-MGF (PEGylated Mechano Growth Factor)
Published sources checked
A source-linked reference on the identity and evidence context of PEG-MGF (PEGylated Mechano Growth Factor). Sources checked 6 September 2026.
Qualified clinical review pending
Hair Growth
2 peptides
GHK-Cu (Topical)
Published sources checked
A source-linked reference on the identity and evidence context of GHK-Cu (Topical). Sources checked 6 September 2026.
Qualified clinical review pending
PTD-DBM
Published sources checked
A source-linked reference on the PTD-DBM compound record. Sources checked 6 September 2026.
Qualified clinical review pending
Cosmetic
9 peptides
AHK-Cu
Published sources checked
A source-linked reference on the identity and evidence context of AHK-Cu. Sources checked 6 September 2026.
Qualified clinical review pending
Botulinum Toxin
Published sources checked
A source-linked medicine reference on Botulinum Toxin, its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
GLOW-50 (GHK-Cu + TB-500 + BPC-157)
Identity unresolved
An identity check for the GLOW-50 blend label, with ingredient-specific limits and no assumed formula.
Qualified clinical review pending
GLOW-70 (GHK-Cu + TB-500 + BPC-157)
Identity unresolved
Why GLOW-70 is a commercial blend label rather than a verified improvement over another GLOW product.
Qualified clinical review pending
GLOW-80 (GHK-Cu + TB-500 + BPC-157 + KPV)
Identity unresolved
A source check of the four-component GLOW-80 label, particularly the extra uncertainty introduced by KPV.
Qualified clinical review pending
Matrixyl
Identity unresolved
A reference record for Matrixyl. Its exact identity is unresolved after targeted source searches on 6 September 2026.
Qualified clinical review pending
Melanotan I (Afamelanotide)
Published sources checked
A source-linked medicine reference on Melanotan I (Afamelanotide), its documented context and safety boundaries. Sources checked 6 September 2026.
Qualified clinical review pending
Melanotan II
Published sources checked
A source-linked reference on the identity and evidence context of Melanotan II. Sources checked 6 September 2026.
Qualified clinical review pending
SNAP-8
Published sources checked
A source-linked reference on SNAP-8, also recorded as acetyl octapeptide-3. Sources checked 6 September 2026.
Qualified clinical review pending
Other
1 peptide